Julphar Diabetes is the division of Julphar that manages the
manufacturing and commercialisation of diabetes products, which
include oral antidiabetics and insulin. It has become one of the
Middle East's leaders in offering world-class treatment for both
Type 1 and Type 2 diabetes and a comprehensive portfolio of high
quality, affordable products.
Our 150 million-dollar
biopharmaceutical manufacturing facility launched in 2012 is
entirely dedicated to manufacturing the API of human insulin and
insulin analogues.
Julphar Diabetes has the capacity to produce 1500 kg of
recombinant human insulin and insulin analogues crystals (rDNA),
equivalent to 40 million vials of insulin per year. This positions
Julphar among the largest manufactures of insulin in the world, and
the only one of its kind in the Middle East.
